Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU
June 29 2022 - 8:00AM
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines
company, announced today participation and presentations at the
following conferences:
FASEB’s The Genome Engineering Conference: Cutting-Edge
Research and Applications on June 29, 2022 at 5:30 p.m. WET/12:30
p.m. ET in Lisbon, Portugal Homology will deliver an oral
presentation titled, “Molecular Characterization of In Vivo Editing
in Human Hepatocytes and a PKU Mouse Model using rAAVHSCs,” which
confirms the precision of homologous recombination-based
integration of HMI-103 nuclease-free gene editing candidate for
phenylketonuria (PKU) using genome-wide assays.
2022 NPKUA Conference on July 7-10, 2022 in Vancouver,
WAHomology presentations include:
- “Gene Editing and Gene Therapy for PKU,” during the panel
session, “What’s New in PKU? (Emerging Therapies, Research, Foods
& Beyond)” on July 8 at 3:30 p.m. PT; and
- “Preclinical Data Supporting the First‐In‐Human Gene Editing
Study For PKU, pheEDIT,” during the poster session on July 9 at
3:00 p.m. PT.
Homology Medicines is conducting two clinical trials for adults
with PKU. The pheEDIT trial is evaluating HMI-103, a one-time gene
editing product candidate designed to integrate the PAH gene into
the genome for a permanent correction. The pheNIX trial is
evaluating HMI-102, a one-time gene therapy product candidate that
is designed to deliver working copies of the PAH gene to liver
cells.
About Homology Medicines, Inc.Homology
Medicines, Inc. is a clinical-stage genetic medicines company
dedicated to transforming the lives of patients suffering from rare
diseases by addressing the underlying cause of the disease. The
Company’s clinical programs include HMI-102, an investigational
gene therapy for adults with phenylketonuria (PKU); HMI-103, a gene
editing candidate for PKU; and HMI-203, an investigational gene
therapy for Hunter syndrome. Additional programs focus on
metachromatic leukodystrophy (MLD), paroxysmal nocturnal
hemoglobinuria (PNH) and other diseases. Homology’s proprietary
platform is designed to utilize its family of 15 human
hematopoietic stem cell-derived adeno-associated virus (AAVHSCs)
vectors to precisely and efficiently deliver genetic medicines in
vivo through a gene therapy or nuclease-free gene editing modality,
as well as to deliver one-time gene therapy to produce antibodies
throughout the body through the GTx-mAb platform. Homology has a
management team with a successful track record of discovering,
developing and commercializing therapeutics with a focus on rare
diseases. Homology believes its initial clinical data and
compelling preclinical data, scientific and product development
expertise and broad intellectual property position the Company as a
leader in genetic medicines. For more information, visit
www.homologymedicines.com.
Company Contacts:Theresa McNeelyChief
Communications Officer and Patient
Advocatetmcneely@homologymedicines.com781-301-7277Media
Contact:Cara Mayfield Vice President, Patient Advocacy and
Corporate Communications cmayfield@homologymedicines.com
781-691-3510
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Sep 2023 to Sep 2024